November 24, 2020

Strongbridge Biopharma plc Announces Publication of Secondary Endpoints Data from Phase 3 SONICS Study of RECORLEV™ (levoketoconazole) for the Treatment of Endogenous Cushing’s Syndrome in the Journal, Pituitary

 RECORLEV™ (levoketoconazole) Treatment Resulted in Significantly Improved Clinician-Assessed Signs and Symptoms and Patient-Reported Outcomes of Cushing’s Syndrome ~ D...
Read more
November 24, 2020

Targovax demonstrates encouraging survival data for ONCOS-102 in mesothelioma

An 18-month analysis shows that median Overall Survival (mOS) will be at least 18.2 months for first-line patients receiving ONCOS-102 plus chemotherapy, compared to mOS of 14....
Read more
November 19, 2020

SynOx Therapeutics raises €37M in Series A Financing

HealthCap and Medicxi co-lead, joined by Forbion and Gimv Financing to develop emactuzumab to improve the lives of patients with tenosynovial giant cell tumours Dublin, I...
Read more
November 19, 2020

INTERIM REPORT Q3 2020

November 19, 2020 Summary Financial overview July 1 – September 30, 2020 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 383.4 M (loss: 189....
Read more
November 19, 2020

Nordic Nanovector completes enrolment into second safety cohort of follicular lymphoma patients in Archer-1 Phase 1b Betalutin®/rituximab combination trial

Oslo, Norway, 19 November 2020 Nordic Nanovector ASA (OSE: NANO) announces that it enrolled the final two patients into the second safety cohort of its Phase 1 Archer-...
Read more
November 19, 2020

Nordic Nanovector ASA: Results for the Third Quarter 2020

Oslo, Norway, 19 November 2020 Nordic Nanovector ASA (OSE: NANO) announces its results for the third quarter 2020. A live webcast presentation by Nordic Nanovector's m...
Read more
November 18, 2020

Vivet Therapeutics and Pfizer Inc. Announce FDA Authorization to Proceed with GATEWAY, the Phase 1/2 Study for VTX-801, Vivet’s Investigational Gene Therapy for Wilson Disease

PARIS, France and NEW YORK, N.Y.—November 18, 2020— Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing treatments for inher...
Read more
November 18, 2020

SPRUCE BIOSCIENCES REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

–Successful Initiation of Late-Stage CAHmelia Program in Adult Classic CAH– –FDA and EMA Scientific Advice Support Plans in Pediatric Classic CAH Program– –IPO Results ...
Read more
November 16, 2020

Vicore Pharma recruits the first patient in the phase II Proof-of-Concept study in idiopathic pulmonary fibrosis

Gothenburg, November 16, 2020 – Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innovative medicines for rare lung disorders, today announce...
Read more
November 13, 2020

InCarda Therapeutics Presents Positive New Data from Phase 2 Study of InRhythm™ in Patients with Paroxysmal Atrial Fibrillation at American Heart Association Scientific Sessions 2020

Data Demonstrate Achievement of Rapid Conversions from Atrial Fibrillation to Normal Sinus Rhythm Study Findings Provide Proof of Concept for First-of-its-Kind Inhaled Antiarrhyth...
Read more